Financial Security Advisor Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Financial Security Advisor Inc. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 932 shares of the medical research company’s stock, valued at approximately $378,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CBIZ Investment Advisory Services LLC increased its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at about $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Barclays boosted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Raymond James Financial restated an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $593.43.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $534.92 on Friday. The business’s 50 day simple moving average is $487.44 and its 200-day simple moving average is $448.31. The firm has a market capitalization of $201.99 billion, a price-to-earnings ratio of 30.94, a price-to-earnings-growth ratio of 2.91 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.